Predicted mechanisms of resistance to mTOR inhibitors

R. T. Kurmasheva, S. Huang, Peter J Houghton

Research output: Contribution to journalShort survey

81 Citations (Scopus)

Abstract

The serine/threonine kinase, mTOR (mammalian Target of Rapamycin) has become a focus for cancer drug development. Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell growth by retarding cells in G1 phase or potentially inducing apoptosis. Currently, both rapamycin and several analogues are being evaluated as anticancer agents in clinical trials. Results indicate that many human cancers have intrinsic resistance and tumours initially sensitive to rapamycins become refractory, demonstrating acquired resistance. Here, we consider mechanisms of resistance to inhibitors of mTOR.

Original languageEnglish (US)
Pages (from-to)955-960
Number of pages6
JournalBritish Journal of Cancer
Volume95
Issue number8
DOIs
StatePublished - Oct 23 2006
Externally publishedYes

Fingerprint

Sirolimus
Neoplasms
Protein-Serine-Threonine Kinases
G1 Phase
Antineoplastic Agents
Clinical Trials
Apoptosis
Growth
Pharmaceutical Preparations

Keywords

  • Cap-dependent translation
  • Clinical resistance
  • Kinase inhibitors
  • Mammalian target of rapamycin (mTOR)
  • Rapamycin
  • Resistance mechanisms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Predicted mechanisms of resistance to mTOR inhibitors. / Kurmasheva, R. T.; Huang, S.; Houghton, Peter J.

In: British Journal of Cancer, Vol. 95, No. 8, 23.10.2006, p. 955-960.

Research output: Contribution to journalShort survey

Kurmasheva, R. T. ; Huang, S. ; Houghton, Peter J. / Predicted mechanisms of resistance to mTOR inhibitors. In: British Journal of Cancer. 2006 ; Vol. 95, No. 8. pp. 955-960.
@article{ead74933bb7b401c93a3a5e18971ce21,
title = "Predicted mechanisms of resistance to mTOR inhibitors",
abstract = "The serine/threonine kinase, mTOR (mammalian Target of Rapamycin) has become a focus for cancer drug development. Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell growth by retarding cells in G1 phase or potentially inducing apoptosis. Currently, both rapamycin and several analogues are being evaluated as anticancer agents in clinical trials. Results indicate that many human cancers have intrinsic resistance and tumours initially sensitive to rapamycins become refractory, demonstrating acquired resistance. Here, we consider mechanisms of resistance to inhibitors of mTOR.",
keywords = "Cap-dependent translation, Clinical resistance, Kinase inhibitors, Mammalian target of rapamycin (mTOR), Rapamycin, Resistance mechanisms",
author = "Kurmasheva, {R. T.} and S. Huang and Houghton, {Peter J}",
year = "2006",
month = "10",
day = "23",
doi = "10.1038/sj.bjc.6603353",
language = "English (US)",
volume = "95",
pages = "955--960",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Predicted mechanisms of resistance to mTOR inhibitors

AU - Kurmasheva, R. T.

AU - Huang, S.

AU - Houghton, Peter J

PY - 2006/10/23

Y1 - 2006/10/23

N2 - The serine/threonine kinase, mTOR (mammalian Target of Rapamycin) has become a focus for cancer drug development. Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell growth by retarding cells in G1 phase or potentially inducing apoptosis. Currently, both rapamycin and several analogues are being evaluated as anticancer agents in clinical trials. Results indicate that many human cancers have intrinsic resistance and tumours initially sensitive to rapamycins become refractory, demonstrating acquired resistance. Here, we consider mechanisms of resistance to inhibitors of mTOR.

AB - The serine/threonine kinase, mTOR (mammalian Target of Rapamycin) has become a focus for cancer drug development. Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell growth by retarding cells in G1 phase or potentially inducing apoptosis. Currently, both rapamycin and several analogues are being evaluated as anticancer agents in clinical trials. Results indicate that many human cancers have intrinsic resistance and tumours initially sensitive to rapamycins become refractory, demonstrating acquired resistance. Here, we consider mechanisms of resistance to inhibitors of mTOR.

KW - Cap-dependent translation

KW - Clinical resistance

KW - Kinase inhibitors

KW - Mammalian target of rapamycin (mTOR)

KW - Rapamycin

KW - Resistance mechanisms

UR - http://www.scopus.com/inward/record.url?scp=33750211376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750211376&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6603353

DO - 10.1038/sj.bjc.6603353

M3 - Short survey

C2 - 16953237

AN - SCOPUS:33750211376

VL - 95

SP - 955

EP - 960

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -